Pharmacopeia, Inc. (NASDAQ: PCOP), a clinical development stage biopharmaceutical company, is focused on discovering and developing innovative small molecule therapeutics to attend to significant medical needs. The company’s broad portfolio of clinical and preclinical candidates are currently under development internally or with partners, including nine clinical compounds in Phase 2 or Phase 1 development. For further information, visit the Company’s web site at www.pcop.com.
- 17 years ago
QualityStocks
Pharmacopeia, Inc. (NASDAQ: PCOP)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – Datavault AI Inc. (NASDAQ: DVLT) Issues Investor Update Highlighting Accelerated Revenue Growth, Global Partnerships, and Platform Expansion
Datavault AI (NASDAQ: DVLT), a leader in data monetization, credentialing, and digital engagement technologies, today…
-
QualityStocksNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) and Sapu Bioscience Publish Landmark Review Defining Sub-15 nm Nanoparticles as New Frontier in Drug Delivery
Oncotelic Therapeutics (OTCQB: OTLC), and joint venture partner Sapu Bioscience today announced the publication of…
-
QualityStocksNewsBreaks – Newton Golf Company Inc. (NASDAQ: NWTG) to Host Webcast and Investor Q&A Following Q3 2025 Financial Results
Newton Golf Company (NASDAQ: NWTG), a technology-forward golf company focused on performance-driven innovation, today announced…